ScreenerHero

ABCL AbCellera Biologics Inc.

NAS · US · Healthcare · Biotechnology · abcellera.com
12.83USD-2.43%Mkt Cap: 4.16B $P/E: —

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Pha…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap4.16B USD
Enterprise Value3.63B USD
Revenue (TTM)66.17M USD
Gross Profit-131.60M USD
Net Income (TTM)-146.41M USD
Revenue/Share0.22 USD
Last Price12.83 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees562
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-16.86
PEG—
EV/EBITDA-18.14
EV/Revenue54.82
P/S64.40
P/B4.50
EPS (TTM)-0.51
EPS (Forward)-0.78
52W Range
2.74582% of range15.02
52W High15.02 USD
52W Low2.745 USD
Profitability
Gross Margin-198.88%
Oper. Margin-1550.05%
EBITDA Margin0.00%
Profit Margin-194.88%
ROE-15.14%
ROA-10.79%
Growth
Revenue Growth-76.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-131.29M USD
CapEx (TTM)42.77M USD
FCF Margin-70.17%
FCF Yield-1.12%
Net Debt-404.49M USD
Net Debt/EBITDA2.02
Balance Sheet
Debt/Equity0.15
Current Ratio12.77
Quick Ratio11.23
Book Value/Sh2.92 USD
Cash/Share1.76 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)16.70 USD
Upside (mean)+30.2%
Target Range9.000 USD – 30.00 USD
9.000+30.2% to mean30.00
# Analysts10
Ownership
Shares Out.324.05M
Float209.04M
Insiders21.74%
Institutions37.19%
Short Interest
Short Ratio6.4d
Short % Float13.34%
Short % Out.10.47%
Shares Short33.93M
Short (prev mo.)41.34M
Technical
SMA 5010.70 (+19.9%)
SMA 2006.033 (+112.6%)
Beta1.41
S&P 52W Chg16.45%
Avg Vol (30d)5.11M
Avg Vol (10d)5.39M
Technical Indicators
RSI (14)55.0
MACD0.8705
MACD Signal1.0019
MACD Hist.-0.1314
BB Upper15.16 USD
BB Middle12.64 USD
BB Lower10.12 USD
BB Width39.89%
ATR (14)0.8466 USD
Vol Ratio (20d)1.02x